Cost-Effectiveness of High-Risk Human Papillomavirus Testing with Messenger RNA Versus DNA under United States Guidelines for Cervical Cancer Screening

Journal of Lower Genital Tract Disease

Volumn 19, Issue 4, 2015, Pages 333-339

  Ting, Jie ^a   Smith, Jennifer S ^b,c   Myers, Evan R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cervical cancer; cost effectiveness; HPV Testing; US screening guidelines

Indexed keywords

MESSENGER RNA; VIRUS DNA; VIRUS RNA;

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIDDEN MARKOV MODEL; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LIFE EXPECTANCY; MRNA EXPRESSION ASSAY; PRACTICE GUIDELINE; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; MOLECULAR DIAGNOSIS; PAPILLOMAVIRIDAE; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADULT; AGED; COST-BENEFIT ANALYSIS; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PRACTICE GUIDELINES AS TOPIC; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84942415538     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0000000000000143     Document Type: Article

References (25)

1. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7,932 women. Br J Cancer 2001;84:1616-23.
2. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
3. Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8,466 patients. Br J Cancer 2003;88:1570-7.
4. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(Suppl 5):F88-99.
5. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
6. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17:S1-27.
7. Moyer on behalf of the U.S Preventive Services Task Force VA. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012;160:330-8.
8. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17.
9. Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer 2013;132:101-8.
10. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011;129:691-701.
11. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-51.
12. Wu R, Belinson SE, Du H, et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Int J Gynecol Cancer 2010;20:1411-4.
13. Reid J, Wright TC, Stoler M, et al. HPV oncogenic mRNA testing for cervical cancer screening; baseline and longitudinal results from the CLEAR study. Am J Clin Pathol 2015. In press.
14. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
15. Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) - explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health 2013;16:231-50.
16. Kulasingam SL, Havrilesky LJ, Ghebre R, et al. Screening for cervical cancer: a modeling study for the us preventive services task force. J Low Genit Tract Dis 2013;17:193-202.
17. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
18. Stoler MH, Wright TC, Cuzick J, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol 2013;208:e1-8.
19. Genders TSS, Meijboom WB, Meijs MFL, et al. CT coronary angiography in patients suspected of having coronary artery disease: decision making from various perspectives in the face of uncertainty. Radiology 2009;253:734-44.
20. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008;115:947-56.
21. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US. Pharmacoeconomics 2005;23:1107-22.
22. Kim J, Goldie S. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br Med J 2009;339:b3884.
23. Kulasingam SL, Kim JJ, Lawrence WF, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2006;98:92-100.
24. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol 2011;49:557-64.
25. Laine S. FDA approves first human papillomavirus test for primary cervical cancer screening. U.S. Food and Drug Administration. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394773.htm. Published April 24, 2014.